P-selectin glycoprotein ligand-1 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "P-selectin glycoprotein ligand-1" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

5^th place

5^th place

1,626^th place

1,007^th place

2semanticscholar.org

11^th place

8^th place

1immuno-oncologynews.com

low place

low place

18^th place

17^th place

1medicalxpress.com

8,255^th place

low place

doi.org

Veerman KM, Carlow DA, Shanina I, Priatel JJ, Horwitz MS, Ziltener HJ (2012-02-15). "PSGL-1 regulates the migration and proliferation of CD8(+) T cells under homeostatic conditions". Journal of Immunology. 188 (4): 1638–1646. doi:10.4049/jimmunol.1103026. ISSN 1550-6606. PMID 22250093.
Sako D, Chang XJ, Barone KM, Vachino G, White HM, Shaw G, et al. (December 1993). "Expression cloning of a functional glycoprotein ligand for P-selectin". Cell. 75 (6): 1179–1186. doi:10.1016/0092-8674(93)90327-m. PMID 7505206.
Veldman GM, Bean KM, Cumming DA, Eddy RL, Sait SN, Shows TB (1995-07-07). "Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand". The Journal of Biological Chemistry. 270 (27): 16470–16475. doi:10.1074/jbc.270.27.16470. ISSN 0021-9258. PMID 7541799.
Li F, Wilkins PP, Crawley S, et al. (1996). "Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin". J. Biol. Chem. 271 (6): 3255–64. doi:10.1074/jbc.271.6.3255. PMID 8621728.
Wilkins PP, Moore KL, McEver RP, Cummings RD (1995). "Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin". J. Biol. Chem. 270 (39): 22677–80. doi:10.1074/jbc.270.39.22677. PMID 7559387.
Sako D, Comess KM, Barone KM, et al. (1995). "A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding". Cell. 83 (2): 323–31. doi:10.1016/0092-8674(95)90173-6. PMID 7585949. S2CID 65420.
Pouyani T, Seed B (1995). "PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus". Cell. 83 (2): 333–43. doi:10.1016/0092-8674(95)90174-4. PMID 7585950. S2CID 17480260.
Zhang C, Zhang Y, Liu Y, Liu Y, Kageyama S, Shen XD, et al. (June 2017). "A Soluble Form of P Selectin Glycoprotein Ligand 1 Requires Signaling by Nuclear Factor Erythroid 2-Related Factor 2 to Protect Liver Transplant Endothelial Cells Against Ischemia-Reperfusion Injury". American Journal of Transplantation. 17 (6): 1462–1475. doi:10.1111/ajt.14159. PMC 5444987. PMID 27977895.
Sun X, Sammani S, Hufford M, Sun BL, Kempf CL, Camp SM, et al. (January 2023). "Targeting SELPLG/P-selectin glycoprotein ligand 1 in preclinical ARDS: Genetic and epigenetic regulation of the SELPLG promoter". Pulmonary Circulation. 13 (1): e12206. doi:10.1002/pul2.12206. PMC 9982077. PMID 36873461.
Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, et al. (May 2016). "PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion". Immunity. 44 (5): 1190–203. doi:10.1016/j.immuni.2016.04.015. PMC 4908967. PMID 27192578.; Lay summary in: Kegel M (1 June 2016). "Immune Factor Seen to Control T-Cell Checkpoints Involved in Spread of Cancers and Infections". Immune-onocology News.
Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. (October 2019). "VISTA is an acidic pH-selective ligand for PSGL-1". Nature. 574 (7779): 565–570. Bibcode:2019Natur.574..565J. doi:10.1038/s41586-019-1674-5. PMID 31645726.
Hope JL, Otero DC, Bae EA, Stairiker CJ, Palete AB, Faso HA, et al. (May 2023). "PSGL-1 attenuates early TCR signaling to suppress CD8+ T-cell progenitor differentiation and elicit terminal CD8+ Tcell exhaustion". Cell Reports. 42 (5): 112436. doi:10.1016/j.celrep.2023.112436. PMC 10403047. PMID 37115668.; Lay summary in: Sanford Burnham Prebys Medical Discovery Institute (4 May 2023). "Reviving exhausted T cells to tackle immunotherapy-resistant cancers". Medical Press.
DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R (2022-05-03). "Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma". Cancer Immunology Research. 10 (5): 612–625. doi:10.1158/2326-6066.CIR-21-0690. ISSN 2326-6074. PMC 9064985. PMID 35303066.
Novobrantseva T, Manfra D, Ritter J, Razlog M, O'Nuallain B, Zafari M, et al. (August 2024). "Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth". Cancers. 16 (16): 2778. doi:10.3390/cancers16162778. PMC 11352552. PMID 39199551.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000110876 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000048163 – Ensembl, May 2017

harvard.edu

ui.adsabs.harvard.edu

Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. (October 2019). "VISTA is an acidic pH-selective ligand for PSGL-1". Nature. 574 (7779): 565–570. Bibcode:2019Natur.574..565J. doi:10.1038/s41586-019-1674-5. PMID 31645726.

immuno-oncologynews.com

Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, et al. (May 2016). "PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion". Immunity. 44 (5): 1190–203. doi:10.1016/j.immuni.2016.04.015. PMC 4908967. PMID 27192578.; Lay summary in: Kegel M (1 June 2016). "Immune Factor Seen to Control T-Cell Checkpoints Involved in Spread of Cancers and Infections". Immune-onocology News.

medicalxpress.com

Hope JL, Otero DC, Bae EA, Stairiker CJ, Palete AB, Faso HA, et al. (May 2023). "PSGL-1 attenuates early TCR signaling to suppress CD8+ T-cell progenitor differentiation and elicit terminal CD8+ Tcell exhaustion". Cell Reports. 42 (5): 112436. doi:10.1016/j.celrep.2023.112436. PMC 10403047. PMID 37115668.; Lay summary in: Sanford Burnham Prebys Medical Discovery Institute (4 May 2023). "Reviving exhausted T cells to tackle immunotherapy-resistant cancers". Medical Press.

nih.gov

pubmed.ncbi.nlm.nih.gov

Veerman KM, Carlow DA, Shanina I, Priatel JJ, Horwitz MS, Ziltener HJ (2012-02-15). "PSGL-1 regulates the migration and proliferation of CD8(+) T cells under homeostatic conditions". Journal of Immunology. 188 (4): 1638–1646. doi:10.4049/jimmunol.1103026. ISSN 1550-6606. PMID 22250093.
Sako D, Chang XJ, Barone KM, Vachino G, White HM, Shaw G, et al. (December 1993). "Expression cloning of a functional glycoprotein ligand for P-selectin". Cell. 75 (6): 1179–1186. doi:10.1016/0092-8674(93)90327-m. PMID 7505206.
Veldman GM, Bean KM, Cumming DA, Eddy RL, Sait SN, Shows TB (1995-07-07). "Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand". The Journal of Biological Chemistry. 270 (27): 16470–16475. doi:10.1074/jbc.270.27.16470. ISSN 0021-9258. PMID 7541799.
Li F, Wilkins PP, Crawley S, et al. (1996). "Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin". J. Biol. Chem. 271 (6): 3255–64. doi:10.1074/jbc.271.6.3255. PMID 8621728.
Wilkins PP, Moore KL, McEver RP, Cummings RD (1995). "Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin". J. Biol. Chem. 270 (39): 22677–80. doi:10.1074/jbc.270.39.22677. PMID 7559387.
Sako D, Comess KM, Barone KM, et al. (1995). "A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding". Cell. 83 (2): 323–31. doi:10.1016/0092-8674(95)90173-6. PMID 7585949. S2CID 65420.
Pouyani T, Seed B (1995). "PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus". Cell. 83 (2): 333–43. doi:10.1016/0092-8674(95)90174-4. PMID 7585950. S2CID 17480260.
Zhang C, Zhang Y, Liu Y, Liu Y, Kageyama S, Shen XD, et al. (June 2017). "A Soluble Form of P Selectin Glycoprotein Ligand 1 Requires Signaling by Nuclear Factor Erythroid 2-Related Factor 2 to Protect Liver Transplant Endothelial Cells Against Ischemia-Reperfusion Injury". American Journal of Transplantation. 17 (6): 1462–1475. doi:10.1111/ajt.14159. PMC 5444987. PMID 27977895.
Sun X, Sammani S, Hufford M, Sun BL, Kempf CL, Camp SM, et al. (January 2023). "Targeting SELPLG/P-selectin glycoprotein ligand 1 in preclinical ARDS: Genetic and epigenetic regulation of the SELPLG promoter". Pulmonary Circulation. 13 (1): e12206. doi:10.1002/pul2.12206. PMC 9982077. PMID 36873461.
Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, et al. (May 2016). "PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion". Immunity. 44 (5): 1190–203. doi:10.1016/j.immuni.2016.04.015. PMC 4908967. PMID 27192578.; Lay summary in: Kegel M (1 June 2016). "Immune Factor Seen to Control T-Cell Checkpoints Involved in Spread of Cancers and Infections". Immune-onocology News.
Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. (October 2019). "VISTA is an acidic pH-selective ligand for PSGL-1". Nature. 574 (7779): 565–570. Bibcode:2019Natur.574..565J. doi:10.1038/s41586-019-1674-5. PMID 31645726.
Hope JL, Otero DC, Bae EA, Stairiker CJ, Palete AB, Faso HA, et al. (May 2023). "PSGL-1 attenuates early TCR signaling to suppress CD8+ T-cell progenitor differentiation and elicit terminal CD8+ Tcell exhaustion". Cell Reports. 42 (5): 112436. doi:10.1016/j.celrep.2023.112436. PMC 10403047. PMID 37115668.; Lay summary in: Sanford Burnham Prebys Medical Discovery Institute (4 May 2023). "Reviving exhausted T cells to tackle immunotherapy-resistant cancers". Medical Press.
DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R (2022-05-03). "Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma". Cancer Immunology Research. 10 (5): 612–625. doi:10.1158/2326-6066.CIR-21-0690. ISSN 2326-6074. PMC 9064985. PMID 35303066.
Novobrantseva T, Manfra D, Ritter J, Razlog M, O'Nuallain B, Zafari M, et al. (August 2024). "Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth". Cancers. 16 (16): 2778. doi:10.3390/cancers16162778. PMC 11352552. PMID 39199551.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: SELPLG selectin P ligand".
Zhang C, Zhang Y, Liu Y, Liu Y, Kageyama S, Shen XD, et al. (June 2017). "A Soluble Form of P Selectin Glycoprotein Ligand 1 Requires Signaling by Nuclear Factor Erythroid 2-Related Factor 2 to Protect Liver Transplant Endothelial Cells Against Ischemia-Reperfusion Injury". American Journal of Transplantation. 17 (6): 1462–1475. doi:10.1111/ajt.14159. PMC 5444987. PMID 27977895.
Sun X, Sammani S, Hufford M, Sun BL, Kempf CL, Camp SM, et al. (January 2023). "Targeting SELPLG/P-selectin glycoprotein ligand 1 in preclinical ARDS: Genetic and epigenetic regulation of the SELPLG promoter". Pulmonary Circulation. 13 (1): e12206. doi:10.1002/pul2.12206. PMC 9982077. PMID 36873461.
Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, et al. (May 2016). "PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion". Immunity. 44 (5): 1190–203. doi:10.1016/j.immuni.2016.04.015. PMC 4908967. PMID 27192578.; Lay summary in: Kegel M (1 June 2016). "Immune Factor Seen to Control T-Cell Checkpoints Involved in Spread of Cancers and Infections". Immune-onocology News.
Hope JL, Otero DC, Bae EA, Stairiker CJ, Palete AB, Faso HA, et al. (May 2023). "PSGL-1 attenuates early TCR signaling to suppress CD8+ T-cell progenitor differentiation and elicit terminal CD8+ Tcell exhaustion". Cell Reports. 42 (5): 112436. doi:10.1016/j.celrep.2023.112436. PMC 10403047. PMID 37115668.; Lay summary in: Sanford Burnham Prebys Medical Discovery Institute (4 May 2023). "Reviving exhausted T cells to tackle immunotherapy-resistant cancers". Medical Press.
DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R (2022-05-03). "Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma". Cancer Immunology Research. 10 (5): 612–625. doi:10.1158/2326-6066.CIR-21-0690. ISSN 2326-6074. PMC 9064985. PMID 35303066.
Novobrantseva T, Manfra D, Ritter J, Razlog M, O'Nuallain B, Zafari M, et al. (August 2024). "Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth". Cancers. 16 (16): 2778. doi:10.3390/cancers16162778. PMC 11352552. PMID 39199551.

semanticscholar.org

api.semanticscholar.org

Sako D, Comess KM, Barone KM, et al. (1995). "A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding". Cell. 83 (2): 323–31. doi:10.1016/0092-8674(95)90173-6. PMID 7585949. S2CID 65420.
Pouyani T, Seed B (1995). "PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus". Cell. 83 (2): 333–43. doi:10.1016/0092-8674(95)90174-4. PMID 7585950. S2CID 17480260.

worldcat.org

search.worldcat.org

Veerman KM, Carlow DA, Shanina I, Priatel JJ, Horwitz MS, Ziltener HJ (2012-02-15). "PSGL-1 regulates the migration and proliferation of CD8(+) T cells under homeostatic conditions". Journal of Immunology. 188 (4): 1638–1646. doi:10.4049/jimmunol.1103026. ISSN 1550-6606. PMID 22250093.
Veldman GM, Bean KM, Cumming DA, Eddy RL, Sait SN, Shows TB (1995-07-07). "Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand". The Journal of Biological Chemistry. 270 (27): 16470–16475. doi:10.1074/jbc.270.27.16470. ISSN 0021-9258. PMID 7541799.
DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R (2022-05-03). "Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma". Cancer Immunology Research. 10 (5): 612–625. doi:10.1158/2326-6066.CIR-21-0690. ISSN 2326-6074. PMC 9064985. PMID 35303066.